This month on TGen Talks, we get an insider’s perspective on how today’s biomedical research translates into tomorrow's treatments. We sit down with Stephanie Pond, Ph.D., Vice President of Emerging Opportunities at TGen.
We’ll Learn about the crucial role of TGen’s START and EDP programs – the Scientific Technology Assessment Research Team and Enterprise Directed Programs – in accelerating this process.
Dr. Pond explains how her team works to identify gaps in current research tools, partner with biotechnology companies to develop new technologies, and help commercialize TGen’s research discoveries. She highlights how advances in multiomics, single-cell sequencing, and spatial technologies are transforming biomedical research and enabling new diagnostic tests and treatments. Dr. Pond also discusses TGen's Enterprise Directed Programs, which focuses on taking research discoveries and developing scalable clinical tests and products.
Join us to hear Dr. Pond’s passion for technology and science and her dedication to bringing personalized medicine to life, faster.
